Announces

Exicure Announces Approval of $8.7 Million Equity Financing and Executive/Board Changes

Exicure, Inc. (Nasdaq: XCUR, “Exicure” or the “Company”), today announced that its stockholders approved a second investment of $8.7 million from HiTron Systems Inc. (“HiTron”), a publicly listed company on the KOSPI exchange in South Korea. This approval was in…

Read MoreExicure Announces Approval of $8.7 Million Equity Financing and Executive/Board Changes

Vertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily, next-generation CFTR (cystic fibrosis transmembrane conductance regulator) modulator. ALYFTREK is approved for the treatment of cystic fibrosis (CF) in…

Read MoreVertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment

FDA Approves Pfizer’s BRAFTOVI® for First-Line BRAF V600E-Mutant Colorectal Cancer

Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) as a treatment for patients with metastatic…

Read MoreFDA Approves Pfizer’s BRAFTOVI® for First-Line BRAF V600E-Mutant Colorectal Cancer

ZIVO Bioscience Reports Early Efficacy of Proprietary Ingredients Against Avian Influenza

ZIVO Bioscience, Inc. (OTCQB: ZIVO), a leading biotech and agtech R&D company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced positive preliminary results from a recent study. Conducted in collaboration with the University…

Read MoreZIVO Bioscience Reports Early Efficacy of Proprietary Ingredients Against Avian Influenza

Quantum-Si Unveils Advances in Protein Variant Detection with ProteoVue™ Software

Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced the submission of a new preprint paper to BioRxiv, showcasing the power of its proprietary bioinformatics tool, ProteoVue, in detecting and quantifying Single Amino Acid Variants (SAAVs). The…

Read MoreQuantum-Si Unveils Advances in Protein Variant Detection with ProteoVue™ Software